nuvolanevicata / Shutterstock.com
20 March 2015Big PharmaTrevor Cook
Market exclusivity: Lucky orphans
Since 2001, the EU has had under Regulation No. 141/2000 a modified regulatory regime that provides incentives to develop orphan medicinal products—those that treat rare diseases with patient populations of generally less than 250,000—within the EU.
